Beckley Psytech and Empatica are collaborating to support the collection and analysis of data in Beckley Psytech’s future clinical trials.
The partnership will capture behavioural and physiological signals and predictive biomarkers in Beckley Psytech’s upcoming Phase 2 clinical trials. To do this, Beckley Psytech will harness Empatica’s medical-grade EmbracePlus wearable and software.
The trials will be evaluating the use of 5-MeO-DMT in combination with psychotherapy in the treatment of treatment resistant depression (TRD).
Empatica, Inc., specialises in medical wearables and digital biomarkers, offering continuous, passive and unobtrusive monitoring for patients with neurological conditions. Beckley has stated the partnership is the latest step in its digital strategy to develop personalised treatment programmes for patients in need.
The digital enhancement of the psychedelic treatment pathway aims to support patients before, during and after treatment through the application of novel, predictive biomarkers which will potentially identify early signals of patient response and relapse.
CEO of Beckley Psytech, Cosmo Feilding Mellen, said: “As we look to enhance the safety and effectiveness of our psychedelic treatments with patient-centric digital tools, this partnership with Empatica accelerates our strategy of creating an integrated treatment model to ensure patients are fully supported through the treatment journey.
“We are thrilled to be working with Empatica, a pioneering digital health company, through our upcoming clinical trials and look forward to further evolving our understanding of how digital tools can support and potentially improve outcomes for patients with neurological and psychiatric conditions.”
Beckley Psytech aims to establish a complete, end-to-end personalised psychedelic treatment programme, combining advanced digital phenotyping capabilities, such as those developed by Empatica, with psychedelic-assisted psychotherapy.
The company has stated that this approach will allow clinicians to provide patients with continuous access to personalised therapy support beyond their treatment, delivering potentially improved outcomes and safety for patients and healthcare systems.
Matteo Lai, CEO of Empatica, commented: “We couldn’t be more excited to collaborate with Beckley Psytech on this important project, especially since over the past two years, we have witnessed how critical mental health and depression have become globally.
“The potential of psychedelic treatments in the field can help millions of patients, and Empatica is honoured to contribute its technology in one of the world’s first trials with psychedelics and digital tools, to advance these novel therapies with targeted help and better engagement.”
[activecampaign form=52]
